Samuel P. Wertheimer, Ph.D.
Dr. Wertheimer focuses on scientific and clinical development issues confronting public and private companies. Prior to joining Brookline, Dr. Wertheimer was a Partner in the private equity group at OrbiMed Advisors, a leading healthcare investment firm. While at OrbiMed Dr. Wertheimer helped to raise four venture capital funds totaling more than $1.4 billion in committed capital. He led investments in companies that brought to market several drugs including Treanda®, Cayston®, Orbactiv® and Horizant®. He has served on the board of directors of both private and public companies.
Dr. Wertheimer received his B.A. from The Johns Hopkins University, his M.P.H with honors from Yale University and his Ph.D. from New York University.